- Home
- CTSO vs VERU Comparison
CTSO vs VERU Comparison
Compare CTSO & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTSO
- VERU
- Stock Information
- Founded
- CTSO 1997
- VERU 1971
- Country
- CTSO United States
- VERU United States
- Employees
- CTSO N/A
- VERU N/A
- Industry
- CTSO Medical/Dental Instruments
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- CTSO Health Care
- VERU Health Care
- Exchange
- CTSO Nasdaq
- VERU Nasdaq
- Market Cap
- CTSO 68.2M
- VERU 76.9M
- IPO Year
- CTSO N/A
- VERU 1990
- Fundamental
- Price
- CTSO $0.84
- VERU $0.51
- Analyst Decision
- CTSO Buy
- VERU Strong Buy
- Analyst Count
- CTSO 2
- VERU 2
- Target Price
- CTSO $5.50
- VERU $4.00
- AVG Volume (30 Days)
- CTSO 149.4K
- VERU 3.3M
- Earning Date
- CTSO 05-14-2025
- VERU 05-08-2025
- Dividend Yield
- CTSO N/A
- VERU N/A
- EPS Growth
- CTSO N/A
- VERU N/A
- EPS
- CTSO N/A
- VERU N/A
- Revenue
- CTSO $35,332,238.00
- VERU $16,886,419.00
- Revenue This Year
- CTSO $18.72
- VERU N/A
- Revenue Next Year
- CTSO $19.75
- VERU N/A
- P/E Ratio
- CTSO N/A
- VERU N/A
- Revenue Growth
- CTSO 15.37
- VERU 134.43
- 52 Week Low
- CTSO $0.70
- VERU $0.45
- 52 Week High
- CTSO $1.61
- VERU $1.42
- Technical
- Relative Strength Index (RSI)
- CTSO 41.67
- VERU 47.70
- Support Level
- CTSO $0.81
- VERU $0.48
- Resistance Level
- CTSO $0.90
- VERU $0.67
- Average True Range (ATR)
- CTSO 0.06
- VERU 0.04
- MACD
- CTSO 0.00
- VERU 0.00
- Stochastic Oscillator
- CTSO 32.77
- VERU 14.84
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.